Trillion-dollar value inflection point has arrived, PegBio (02565.HK) innovative drug "PDK-800" successfully approved!

According to the Securities Times APP, a significant event in the innovative drug investment sector GLP-1 track once again occurred - Peg-bio (02565.HK) independently developed weekly GLP-1RA formulation semaglutide (Ozempic) has officially been approved by the Chinese National Medical Products Administration for listing, for the treatment of type 2 diabetes (T2DM). This is not only a new drug approval announcement, but also a potentially key turning point in the investment value of Peg-bio, which investors should pay close attention to.